OrthoPediatrics Q3 revenue rises, beats estimates
KIDS•OrthoPediatrics' third-quarter revenue rose 19% year over year to $72.7 million, above the $68.5 million consensus estimate. The company raised its 2026 revenue guidance to $270 million-$273 million.
1. Quarterly results
OrthoPediatrics reported third-quarter revenue of $72.7 million, up 19% year over year and above the $68.5 million consensus estimate. The company posted a net loss of $5.93 million, or $0.25 per share, and adjusted EBITDA of $6.9 million, below the $8.38 million consensus estimate. Gross margin was 74%.
2. Raised guidance
The company raised its 2026 revenue outlook to $270 million-$273 million from $265 million-$269 million. It expects adjusted EBITDA of about $25 million and breakeven free cash flow in 2026.
3. Growth drivers
OrthoPediatrics attributed revenue growth mainly to global Trauma and Deformity and OPSB product sales, increased procedure volumes, and new or expanded product lines including Cannulated Screws, PNP Femur, PediPlates, 3P Hip and OPSB. The company expects new product launches to drive financial performance in coming years.
